Anaptysbio ANAB
Anaptysbio Q1 FY24: revenue $7.2M; diluted EPS −$1.64
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001370053-24-000027
- Document
- 10-Q
- Exhibit 10.28
- Material contract
Key figures from this report
These are the numbers Anaptysbio reported for Q1 FY24, the quarter ended Mar 31, 2024, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$7.2MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Net income−$43.9MNo year-earlier figure tagged10-Q income statement, on EDGAR
- Diluted EPS−$1.64No year-earlier figure tagged10-Q income statement, on EDGAR
- Cash and cash equivalents$53.7MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
- Cash from operations−$37.3MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR
Similar companies
Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.
- Amphastar Pharmaceuticals AMPH public float $633M, Jun 30, 2025
- Stoke Therapeutics STOK public float $592M, Jun 30, 2025
- Trevi Therapeutics TRVI public float $588M, Jun 30, 2025
- ImmunityBio IBRX public float $690M, Jun 30, 2025
- Anavex Life Sciences AVXL public float $708M, Mar 31, 2025, over 18 months old